Tonix Pharmaceuticals Announces Enrollment of Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia is Ahead of Schedule
Topline Results Expected Fourth Quarter 2020 Due to Faster than Previously Projected EnrollmentCompletion of Trial Enrollment Anticipated Early Third Quarter […]